Core Cancer Drug Scrutinized


December 16, 2009

The Wall Street Journal

SAN ANTONIO, Texas -- New findings suggest that the risks associated with a class of chemotherapy drugs widely used to treat breast cancer outweighed their benefits in some patients.

The findings, presented at the San Antonio Breast Cancer Symposium on Saturday, renewed a debate over whether the chemotherapy drugs anthracyclines, which have been around since the 1960s, should remain the standard of care in treating breast cancer, or whether newer drugs should be used more frequently instead... Read More